{
  "guideline": {
    "id": "PA166104833",
    "name": "Annotation of FDA Label for abacavir and HLA-B",
    "objCls": "Label Annotation",
    "source": "FDA",
    "version": 47,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166104833",
    "relatedChemicals": [
      {
        "id": "PA448004",
        "name": "abacavir",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA35056",
        "name": "major histocompatibility complex, class I, B",
        "symbol": "HLA-B"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166310761",
      "name": "Recommendation Annotation PA166310761",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA448004",
          "name": "abacavir",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452213200,
        "html": "<p>&quot;All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with ZIAGEN [abacavir] or reinitiation of therapy with ZIAGEN, unless patients have a previously documented HLA-B*5701 allele assessment...ZIAGEN [abacavir] is contraindicated in patients: who have the HLA-B*5701 allele.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*57:01 positive"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product ZIAGEN (abacavir sulfate), NDA020977, ViiV Healthcare Company",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020977"
    }
  ],
  "version": "2024-03-08-14-34"
}